Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Survivin--a universal tumor antigen.

M H Andersen1, Straten P thor

  • 1Tumor Immunology Group, Danish Cancer Society, Copenhagen. mha@cancer.dk

Histology and Histopathology
|April 19, 2002
PubMed
Summary

Survivin, a novel tumor antigen, shows promise for cancer immunotherapy. Its expression across many cancers, unlike melanocyte-specific antigens, offers broad therapeutic potential for cytotoxic T lymphocyte (CTL) responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Working Memory Predicts Long-Term Recognition of Auditory Sequences: Dissociation Between Confirmed Predictions and Prediction Errors.

Scandinavian journal of psychology·2025
Same author

Preliminary validity testing of the eHealth Literacy Questionnaire (eHLQ): a Confirmatory Factor Analysis (CFA) in Norwegian hospitalized patients.

BMC psychology·2023
Same author

Health literacy profiling in persons with psoriasis - A cluster analysis.

Skin health and disease·2022
Same author

Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases.

The British journal of surgery·2019
Same author

A systematic review of quality of life research in medicine and health sciences.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2019
Same author

Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver.

BJS open·2019

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Tumor-associated antigens are targets for cancer immunotherapy, including tissue-specific proteins, cancer-testis antigens, and mutation-derived peptides.
  • Current immunotherapies often use melanocyte-specific antigens, limiting their application to non-melanoma cancers.
  • Tumor antigen heterogeneity and immune selection pose challenges for effective cancer immunotherapy.

Purpose of the Study:

  • To identify and evaluate novel tumor antigens for broad cancer immunotherapy applications.
  • To investigate survivin as a potential universal tumor antigen for inducing cytotoxic T lymphocyte (CTL) responses.
  • To overcome limitations of current antigen-specific cancer immunotherapies.

Main Methods:

  • Identification of tumor antigens based on spontaneous CTL responses in cancer patients.
  • Analysis of survivin expression patterns in various human neoplasms and normal tissues.
  • Evaluation of MHC-restricted survivin epitopes as potential targets for anti-cancer strategies.

Main Results:

  • Survivin identified as a novel tumor antigen with spontaneous CTL responses in cancer patients.
  • Survivin is expressed in most human neoplasms but not in normal differentiated tissues.
  • Downregulation of survivin significantly impairs tumor cell growth potential.

Conclusions:

  • Survivin represents a widely applicable target for anti-cancer immunotherapeutic strategies due to its broad expression in tumors.
  • MHC-restricted survivin epitopes can be utilized to induce specific CTL responses against various cancers.
  • Survivin-based immunotherapy offers a promising approach to overcome limitations of current cancer treatments.

Related Experiment Videos